Biohaven Pharma (BHVN) Reports Positive Degrader Data Achieving > 80% Sustained Reductions in Total IgG with Potential First-in-Class BHV-1300

Go back to Biohaven Pharma (BHVN) Reports Positive Degrader Data Achieving > 80% Sustained Reductions in Total IgG with Potential First-in-Class BHV-1300
(NYSE: BHVN) Delayed: 13.57 --0 (-0%)
Previous Close $13.57    52 Week High
Open $13.57    52 Week Low
Day High $13.57    P/E N/A 
Day Low $13.57    EPS
Volume 45,722